erlotinib hydrochloride has been researched along with mandelalide a in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (mandelalide a) | Trials (mandelalide a) | Recent Studies (post-2010) (mandelalide a) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 11 | 0 | 11 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Humphreys, IR; Ishmael, JE; Mattos, DR; McPhail, KL; Nguyen, MH; Serrill, JD; Smith, AB; Viollet, B; Wan, X | 1 |
1 other study(ies) available for erlotinib hydrochloride and mandelalide a
| Article | Year |
|---|---|
The Marine-Derived Macrolactone Mandelalide A Is an Indirect Activator of AMPK.
Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fibroblasts; Glioblastoma; Humans; Lung Neoplasms; Macrolides; Mammals; Mice; Phosphorylation | 2022 |